Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Zealand cervical screening drive a success

This article was originally published in Clinica

Executive Summary

New Zealand claims that there has been an increased uptake of cervical screening in women from all population groups as a result of a dedicated national awareness campaign. Notably, more Maori and Pacific Islander women have been screened since September 2007 when the campaign was launched and August 2008. Increases of 6% and 11% have been recorded for these population groups, respectively. Overall, a 3% increase in screening has been recorded, according to associate health minister Steve Chadwick. Other successes of the initiative include: 40,000 new enrolments in the screening programme; and a 27% increase in calls to the programme's information line. Under the National Cervical Screening Programme, women between the ages of 20-70 are offered access to cervical screening.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel